Developing innovative therapies in NASH NasdagListed This presentation contains "forward-looking statements" within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical facts, included in this presentation are forward-looking statements. These statements include, but are not limited to, forecasts, targets and estimates with respect to Inventiva's pre-clinical programs and clinical trials, including recruitment, ...

Inventiva S.A. (NASDAQ:IVA) Q2 2022 Earnings Conference Call September 22, 2022 8:00 AM ET Company Participants Frédéric Cren - Co-Founder and CEO Pierre Broqua - Co-Founder and CSO Michael Cooreman - Chief Medical Officer Jean Volatier - Chief Financial Officer Philip Duong - Head, Investment Conference Call Participants Ed Arce - H.C. Wainwright Jeroen Van den Bossche - KBC Securities Alex Cogut - Bryan, Garnier Delphine Le Louët - Société Générale Operator Good day and thank you for standing by. Welcome ...

inventiva | --- | --- | --- | --- | --- | --- | --- | --- | --- | |-----------|-------|------------------------|-------|-------|------------------------------------|-------|-------|-------| | | | | | | | | | | | | | | | | | | | | | | | | | | Developing innovative therapies in | | | | | NASH | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | Corporate Presentation | | | | | | | | June 2022 | | | | | | | | | | | | | | | | | | | EURONEXT DISCLAIMER This presentation contains fo ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 20-F (Mark One) ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☐ SHELL COMPANY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES ...

Inventiva S.A. (NASDAQ:IVA) Q4 2021 Earnings Conference Call March 8, 2022 8:00 AM ET Company Participants Frédéric Cren - Chairman, Chief Executive Officer & Co-Founder Pierre Broqua - Chief Scientific Officer & Co-Founder Michael Cooreman - Chief Medical Officer Jean Volatier - Chief Financial Officer Conference Call Participants Lucy Codrington - Jefferies Jeroen Van den Bossche - KBC Securities Jean-Jacques Le Fur - Bryan, Garnier Ivan Wang - Guggenheim Securities Delphine Le Louët - Société Générale Op ...

Inventiva S.A. (NASDAQ:IVA) Q2 2021 Results Conference Call September 21, 2021 8:00 AM ET Â Company Participants Frédéric Cren - Chairman, CEO and Co-Founder Pierre Broqua - CSO and Co-Founder Michael Cooreman - CMO Jean Volatier - CFO Conference Call Participants Lucy Codrington - Jefferies Lenny Van Steenhuyse - KBC Securities Ed Arce - H.C. Wainwright Zegbeh Jallah - Roth Capital Partners Delphine Le Louët - Société Générale Operator Good day and thank you for standing by. Welcome to InventivaÂ's First H ...

Exhibit 99.1 INVENTIVA S.A. A joint-stock company (société anonyme) with a share capital of 386,593.61euros Registered office: 50, rue de Dijon, 21121 Daix, France Dijon Trade and Companies Register 537 530 255 INTERIM FINANCIAL REPORT FOR THE SIX MONTHS ENDED JUNE 30, 2021 Table of contents | 1. | Interim Financial Report | 2 | | --- | --- | --- | | 1.1. | General overview of activities | 2 | | 1.2. | Significant events in first-half 2021 | 2 | | 1.3. | Recent events and prospects | 5 | | 1.4. | Risk facto ...

inventiva | --- | --- | --- | --- | --- | --- | --- | --- | |-----------|------------------------|-------|-------|------------------------------------|-------|-------|-------| | | | | | | | | | | | | | | | | | | | | | | | Developing innovative therapies in | | | | | | NASH and MPS | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | Corporate Presentation | | | | | | | | June 2021 | | | | | | | | | | | | | | | | | DISCLAIMER This presentation contains forward-looking sta ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 20-F | (Mark One) | | | --- | --- | | ☐ | REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 | | | OR | | ☒ | ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 | | | For the fiscal year ended December 31, 2020 | | | OR | | ☐ | TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 | | | OR | | ☐ | SHELL COMPANY REPORT PU ...

Inventiva S.A. (OTCPK:IVEVF) Q4 2020 Earnings Conference Call March 5, 2021 8:00 AM ET Company Participants Frédéric Cren - Chairman, Chief Executive Officer and Co-Founder Pierre Broqua - Chief Scientific Officer and Co-Founder Michael Cooreman - Chief Medical Officer Jean Volatier - Chief Financial Officer Conference Call Participants Etzer Darout - Guggenheim Lucy Codrington - Jefferies Lenny Van Steenhuyse - KBC Jean-Jacques Le Fur - Bryan, Garnier Zegbeh Jallah - ROTH Capital Michael Morabito - Chardan ...